Fosamax and Osteonecrosis of the Jaw: Understanding the Medical Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Risk Awareness

The legacy of general health and science information has long served as a foundation for public understanding of medication risks and benefits. Within this broad context, the dissemination of knowledge about prescription drugs has historically emphasized patient education and informed consent. As the domain of mass production evolves, the focus naturally shifts from generalized health awareness to specific occupational exposure scenarios. In manufacturing environments, the handling of pharmaceutical compounds introduces distinct risk profiles that differ from patient consumption. The transition from general health literacy to workplace safety considerations becomes particularly relevant when examining substances with established biological effects. This pivot acknowledges that production workers may encounter active pharmaceutical ingredients at higher concentrations and through different routes than end users. The occupational context demands a refined approach to risk communication, moving beyond patient-oriented warnings to address inhalation, dermal contact, and chronic low-level exposure. Such considerations are essential for developing appropriate protective measures and monitoring protocols in industrial settings, where the scale of production amplifies potential exposure pathways. This shift in perspective does not diminish the importance of general health information but rather extends its principles into the specialized realm of occupational health, where the same compounds require distinct evaluation criteria.

Bridging to Fosamax: A Medication with Known Risks

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces the incidence of fractures, including those of the hip and spine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and exposed bone in the jaw, which may be accompanied by purulent discharge or fistula formation. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like Fosamax accumulate in bone tismedical context, particularly at sites of high bone turnover such as the jaw. They inhibit osteoclast activity, which can suppress normal bone remodeling and repair processes. This suppression may impair the jawbone's ability to heal after minor trauma, such as tooth extraction, or in response to infection. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to necrosis. The jawbone's unique structure and high remodeling rate make it particularly susceptible to these effects.

Risk Factors and Epidemiological Evidence

Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not significantly different from placebo. Population-based data provide further context on the risk. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk for an individual patient remains small. The risk is higher in patients with additional risk factors, such as cancer or concomitant therapies.

Causation and Clinical Management

From a causation-focused clinical interpretation, the association between Fosamax and ONJ is supported by multiple lines of evidence: case reports, clinical trial data, and epidemiological studies. The temporal relationship, with onset ranging from days to months after starting the drug, and the recurrence upon rechallenge, support a causal link. However, the low absolute risk and the presence of other risk factors mean that not all patients exposed to Fosamax will develop ONJ. For affected patients, management includes discontinuation of the bisphosphonate, conservative wound care, and avoidance of invasive dental procedures. The risk-benefit profile of Fosamax should be considered, especially for patients at low risk for fracture, where drug discontinuation after 3 to 5 years of use may be appropriate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors. The mechanistic pathways involve suppression of bone remodeling and potential anti-angiogenic effects. While the absolute risk is low, clinicians should be aware of this adverse effect and counsel patients on preventive dental care and the signs and symptoms of ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis. It works by inhibiting bone resorption, which increases bone mass and reduces fracture risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed, non-healing bone in the jaw, often associated with tooth extraction or infection. Fosamax and other bisphosphonates can increase the risk of ONJ by suppressing bone remodeling and reducing blood supply. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, and longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How common is ONJ in patients taking Fosamax?

The absolute risk is low, about 0.05% after 5 years of use. However, the relative risk increases with longer exposure, especially after 2-3 years. (https://pubmed.ncbi.nlm.nih.gov/39400702/)

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.